News
Canadian firm enters race to bring generic Ozempic to market
As the race among drug makers heats up to deliver a generic form of the blockbuster drug Ozempic next year, Vimy Pharmaceuticals Inc., a new entrant to the field, is aiming to produce a made-in-Canada version.
The race to making the Canadian version of Ozempic
Vimy Pharma co-founder and CEO, Dave Suchon, discusses the company and the GLP-1 space in Canada with Andrew Bell on BNN’s “The Open” on October 17, 2025
‘The potential is phenomenal’: Drug maker Vimy Pharma plans to produce made-in-Canada, generic version of Ozempic
Canadian company Vimy Pharma aims to produce a generic version of blockbuster drug Ozempic to provide an affordable option for health-conscious consumers in the country.
‘We’re going to be making it here in Canada,” Dave Suchon, co-founder of Vimy Pharma told BNN Bloomberg in a Friday interview. “We’ve done our research and development here in Canada as well.”
Vimy Pharma’s entry could mark a turning point for Canadian patients and plan sponsors seeking cost-effective solutions for chronic conditions
Affordable Ozempic could soon be within reach for millions of Canadians
The company’s name pays tribute to the Battle of Vimy Ridge, reflecting a sense of national pride and connection to Canada’s scientific heritage. Suchon and Smith said they were inspired by Frederick Banting and Charles Best, who, along with John Macleod and James Collip, discovered insulin in 1921, a breakthrough that transformed diabetes care worldwide.
More than 100 years later, Vimy Pharma hopes to mark the next chapter in Canada’s long history of leadership in diabetes research.
Canadian firm plans homegrown generic of Ozempic as exclusivity nears end
Vimy Pharma Partners with Wounded Warriors Canada, Pledges Portion of Profits to Support Veterans and First Responders
TORONTO, July 8, 2025 — Vimy Pharma, a proudly Canadian pharmaceutical company dedicated to producing high-quality, affordable medicines, today announced a partnership with Wounded Warriors Canada, a national leader in mental health services for Veterans, First Responders, and their families.
As part of this partnership, Vimy Pharma is pledging a percentage of its profits to support Wounded Warriors Canada’s vital programs, which provide life-changing mental health resources and support to those who have served Canada at home and abroad.
TORONTO, May 30, 2025 — Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada.
This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise.
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
Organizational update regarding Dr. Sean Wharton
Vimy Pharma would like to thank Dr. Wharton for his support as Chief Medical Officer and to announce that, effective June 2025, he is no longer in that role.
Vimy Pharma remains committed to its three-part mission to increase access to important medicines for Canadians and contribute to the sustainability of the healthcare system, while supporting Canadian manufacturing. Vimy Pharma would also like to recognize Dr. Wharton for his important work as a global key opinion leader in the field of chronic disease, helping to bring treatment guidelines and options to patients living with chronic disease.